About Humanwell Healthcare Company

Established in 1993 and listed on the Shanghai Stock Exchange in 1997, it is a leading enterprise in the pharmaceutical industry in Hubei Province, one of the top 30 pharmaceutical industry enterprises in China, a national scientific and technological innovation demonstration enterprise, and a leading enterprise in the internationalization of Chinese pharmaceutical preparations. It has established a leading or leading position in various domestic segments such as narcotic drugs, steroidal hormone drugs, and Uyghur folk medicine. It is mainly engaged in R&D, production and sales of pharmaceuticals, and is a leading enterprise in the pharmaceutical industry in Hubei Province and a national technological innovation demonstration enterprise. The main products include fentanyl citrate injections, sufentanyl citrate injections, remifentanil hydrochloride injections, hydromorphone hydrochloride injections, nalbuphine hydrochloride injections, etc. Corporate honors: The company has been selected by the Ministry of Industry and Information Technology's “China's Top 100 Pharmaceutical Industry List” for 13 consecutive years, and selected as the “2022 China Top 500 Manufacturing Enterprises”.